Not Signed In - Biolex Therapeutics Announces Initiation Of Locteron(TM) Phase 2 Clinical Study In Chronic Hepatitis C
Wed, 31 Jan 2007 08:00 AM EST
... Biolex Therapeutics today announced the initiation of a Phase 2a clinical trial of its lead product candidate Locteron(TM), a best-in-class controlled-release interferon alfa. Locteron is being developed as a treatment for chronic hepatitis C, a virus infecting more than four million people in the United States. [click link for full article] ...
Related Topics
- Hepatitis C
- Clinical Trials
- Pharmacology
- Hepatitis B
- Hepatitis A
- Hepatitis
- Autoimmune Hepatitis
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Chronic Fatigue Syndrome
- Pain - Chronic
- Chronic Pain
- Chronic Diseases
- Chronic Hepatitis C: Current Disease Management
- Psychopharmacology
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Lamivudine
- Hepatitis B Immune Globulin
email this page
print this page
bookmark this page
feedback on this page
